Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06943807

Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis

This is a prospective study designed to evaluate the efficacy of a multi-target fecal DNA test for the early detection of gastric cancer. The test combines Helicobacter pylori gene detection with analysis of fecal methylated DNA markers. The primary objective is to assess whether each method, individually or in combination, can facilitate earlier diagnosis of gastric cancer. All participants will undergo the multi-target fecal DNA test and complete the gastric cancer risk questionnaire.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Sample Selection:

The study will be conducted in selected communities within Tongling City, with a total of 10000-15000 residents recruited

Participants Recruitment:

  • Participation is voluntary. All subjects must provide written informed consent at the time of recruitment.
  • Well-trained investigators will conduct face-to-face interviews to administer the gastric cancer risk questionnaire.

Tests and Follow-up:

  • Initial Screening: All participants will provide a stool sample for the multi-target DNA analysis (including H. pylori susceptibility testing and methylated DNA markers) and complete a questionnaire.
  • Definition of Screening Positive: A participant will be considered screening positive if they test positive on the fecal multi-target DNA test or are identified as high-risk through the questionnaire.
  • Diagnostic Workup: All screening-positive individuals will be referred for a confirmatory diagnostic workup. Briefly, the endoscopist will conduct a fiberoptic endoscopy and perform a pathological biopsy.
  • Follow-up: Screening-positive individuals who are not diagnosed with gastric cancer in the first year will be entered into an annual follow-up program.
  • Biobanking: Residual fecal samples will be stored at the biobank of Fudan University Shanghai Cancer Center for future biomarker research.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥40 years, male or female.
  • No contraindications to endoscopy and able to cooperate with endoscopy.
  • Patients must be able to fully understand the informed consent form and be able to sign the informed consent form in person.

Exclusion criteria

  • A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.
  • Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.
  • Severe mental illness or incapacity to participate in the study due to lack of civil behavior.
  • Pregnant or breastfeeding women.
  • Other conditions that the investigator deems inappropriate for participation in the study.

Treatment and study plan

Primary outcomes

  1. Sensitivity and specificity of the fecal multi-target DNA test and questionnaire screening for gastric cancer

    Time frame: 2 years

    To compare the sensitivity and specificity of the fecal multi-target DNA test and questionnaire screening for gastric cancer.

Secondary outcomes

  1. Positive and negative predictive values of the fecal multi-target DNA test and the questionnaire screening method

    Time frame: 2 years

    To compare the positive and negative predictive values of the fecal multi-target DNA test and the questionnaire screening method

  2. Number needed to screen to identify one gastric cancer

    Time frame: 2 years

    To calculate and compare the number of participants needed to screen to identify one case of gastric cancer using the fecal DNA test versus the questionnaire.

  3. Early diagnosis rate of gastric cancer

    Time frame: 2 years

    To compare the early gastric cancer detection rate achieved by the fecal multi-target DNA testing and the questionnaire.

  4. Diagnosis rate of precancerous lesions associated with gastric cancer

    Time frame: 2 years

    To compare the detection rate of the fecal multi-target DNA testing and the questionnaire for precancerous lesions associated with gastric cancer

Other outcomes

  1. Development of a new screening strategy

    Time frame: 2 years

    To perform a comprehensive analysis of the performance of all methods and develop an optimized, evidence-based strategy for population-based gastric cancer screening.

Study contacts

Contact information is provided by the study sponsor or research team.

Dazhi Xu, PhD

CONTACT

[email protected]

86-18121299796

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

A Prospective Study of Gastric Cancer Screening Based on Fecal Multi-Target DNA Analysis Combined With a Risk Questionnaire

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Apr 24, 2025
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.